weekly_roundup
BioTechSign Daily Catalyst Roundup - November 03, 2026
Top BioTechSign catalyst names today: UCBNV, TOI, CMPX, EIKN, ZBIO, INO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 3, 2026
Daily Biotech Catalyst Digest: November 03, 2026
UCBNV leads the current BioTechSign screen at 99.5/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| UCBNV | UCB SA | 99.5 | A | clinical activity 100%, publication signal 75% |
| TOI | The Oncology Institute, Inc. | 86.6 | A | publication signal 100%, clinical activity 100%, dilution risk 65% |
| CMPX | Compass Therapeutics, Inc. | 86.5 | A | clinical activity 100%, short interest 90%, dilution risk 43% |
| EIKN | Eikon Therapeutics, Inc. | 85.3 | A | clinical activity 100%, short interest 70%, dilution risk 45% |
| ZBIO | Zenas BioPharma, Inc. | 83.4 | A | clinical activity 100%, short interest 90%, dilution risk 29% |
| INO | Inovio Pharmaceuticals, Inc. | 82.4 | A | dilution risk 87%, short interest 70% |
Recent Grade-Change Queue
- UCBNV (UCB SA) currently grades A with a 99.5/100 catalyst score. Main inputs: clinical activity 100%, publication signal 75%.
- SNY (Sanofi SA) currently grades B with a 72.9/100 catalyst score. Main inputs: clinical activity 100%, dilution risk 12%, short interest 10%.
- QURE (uniQure NV) currently grades D with a 38.7/100 catalyst score. Main inputs: dilution risk 52%, short interest 50%, PDUFA timing 35%.
- PBYI (Puma Biotechnology Inc) currently grades B with a 79.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 50%.
- OPK (OPKO Health, Inc.) currently grades B with a 68.0/100 catalyst score. Main inputs: clinical activity 83%, short interest 50%, dilution risk 27%.
- ICLR (ICON plc) currently grades C with a 51.2/100 catalyst score. Main inputs: clinical activity 100%, dilution risk 10%, short interest 10%.
- IOVA (Iovance Biotherapeutics) currently grades C with a 58.2/100 catalyst score. Main inputs: clinical activity 67%, short interest 50%, dilution risk 35%.
- EYPT (EyePoint, Inc.) currently grades C with a 50.4/100 catalyst score. Main inputs: short interest 70%, dilution risk 43%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.